Please login to the form below

Not currently logged in
Email:
Password:

Melinta names chief medical officer

Sue Cammarata has experience at Shire and Novartis
Meltina Sue Cammarata

Dr Sue Cammarata has joined Melinta Therapeutics as chief medical officer as the company advances the progress of its late-stage pipeline.

In her new role, Dr Cammarata will lead the company's global development and registration strategy, including the plan for lead product candidate delafloxacin, in phase III for skin infections.

She has prior experience in developing anti-infectives, including Cubicin (daptomycin) during her time at Novartis, where she served as VP and global programme head for the company's immunology and infectious disease franchises from 2008 to 2010.

Dr Cammarata spent seven years at Novartis in total, having joined the company from Pharmacia in 2003. At Pharmacia, she worked on the anti-infective Zyvox (linezolid).

Her most recent role prior to joining Melinta was as VP, clinical research at Shire's human genetic therapies division.

Melinta's CEO Mary Szela said: "The extensive expertise Sue gained while developing and commercialising Cubicin and Zyvox, two billion-dollar anti-infective products that are among the most widely prescribed, will be invaluable as we move our earlier stage antimicrobial candidates into and through the clinic." 

26th November 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics